DFTC yields 11976.05% · JNJ yields 2.14%● Live data
📍 DFTC pulled ahead of the other in Year 1
Combined, DFTC + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DFTC + JNJ for your $10,000?
Defentect Group, Inc. develops and provides IP based alerting system that protects against chemical, biological, radiological, nuclear, and explosive threats. The company offers DM3, a software platform that enables the integration of multiple sensors to coordinate security systems through a simple graphical user interface and initiates communication and data-driven messaging between systems and to emergency personnel; and DefenCall, an iPhone application which links to DM3 and creates a mobile personal safety device and service. It also offers GammaTect Zero, an integration device, which combines an analog-to-digital converter and a communications module; GammaTect Two, a Geiger-Muller based gamma detector that detects gamma radiation above 50 microR/hr; and GammaTect Four, a scintillator-based gamma radiation sensor enabling real-time alerts and gamma radiation isotope identification in an unattended perimeter or portal network. The company was formerly known as Splinternet Holdings, Inc. Defentect Group, Inc. was incorporated in 2000 and is based in New Canaan, Connecticut.
Full DFTC Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.